Traws Pharma, Inc. Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest
Traws Pharma, Inc. (TRAW) had Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest of $1.69 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest
us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest · last filed 2026-08-14
- 2026-06-30: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $1.69M.
- 2026-03-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -$5.31M.
- 2025-12-31: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -$629.00K.
- 2025-09-30: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $4.54M.
| Period end | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest |
|---|---|
| 2026-06-30 | $1.69M 10-Q · filed 2026-08-14 |
| 2026-03-31 | -$5.31M 10-Q · filed 2026-08-14 |
| 2025-12-31 | -$629.00K 10-Q · filed 2026-08-14 |
| 2025-09-30 | $4.54M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $8.26M 10-Q · filed 2026-08-14 |
| 2025-03-31 | $6.00M 10-Q · filed 2026-08-14 |
| 2024-12-31 | -$31.63M 10-Q · filed 2026-08-14 |
| 2024-09-30 | -$2.03M 10-Q · filed 2025-11-13 |
| 2024-06-30 | -$105.52M 10-Q · filed 2025-11-13 |
| 2024-03-31 | $6.01M 10-Q · filed 2025-08-14 |
| 2023-12-31 | $10.67M 10-K · filed 2026-04-15 |
| 2023-09-30 | $14.52M 10-Q · filed 2024-11-14 |
| 2023-06-30 | $18.90M 10-Q · filed 2024-11-14 |
| 2023-03-31 | $22.88M 10-Q · filed 2024-08-15 |
| 2022-12-31 | $28.31M 10-K · filed 2025-03-31 |
| 2022-09-30 | $33.37M 10-Q · filed 2023-11-14 |
| 2022-06-30 | $38.48M 10-Q · filed 2023-11-14 |
| 2022-03-31 | $42.29M 10-Q · filed 2023-08-14 |
| 2021-12-31 | $46.12M 10-K · filed 2024-04-01 |
| 2021-09-30 | $49.67M 10-Q · filed 2022-11-14 |
| 2021-06-30 | $32.99M 10-Q · filed 2022-11-14 |
| 2021-03-31 | $37.15M 10-Q · filed 2022-08-15 |
| 2020-12-31 | $6.17M 10-K · filed 2023-03-30 |
| 2020-09-30 | $12.21M 10-Q · filed 2021-11-15 |
| 2020-06-30 | $15.63M 10-Q · filed 2021-11-15 |
| 2020-03-31 | $21.35M 10-Q · filed 2021-08-16 |
| 2019-12-31 | $11.57M 10-K · filed 2022-03-21 |
| 2019-09-30 | -$6.04M 10-Q · filed 2020-11-16 |
| 2019-06-30 | -$4.55M 10-Q · filed 2020-11-16 |
| 2019-03-31 | -$1.54M 10-Q · filed 2020-08-12 |
| 2018-12-31 | $5.39M 10-K · filed 2021-03-18 |
| 2018-09-30 | $10.86M 10-Q · filed 2019-11-12 |
| 2018-06-30 | $15.91M 10-Q · filed 2019-11-12 |
| 2018-03-31 | -$6.88M 10-Q · filed 2019-08-14 |
| 2017-12-31 | -$10.86M 10-K · filed 2020-03-27 |
| 2017-09-30 | -$6.08M 10-Q · filed 2017-11-09 |
| 2017-06-30 | $442.00K 10-Q · filed 2017-08-14 |
| 2017-03-31 | -$2.71M 10-Q · filed 2017-05-15 |
| 2016-12-31 | $5.13M 10-K · filed 2019-04-01 |
| 2016-09-30 | $10.02M 10-Q · filed 2016-11-14 |
| 2016-06-30 | $2.05M 10-Q · filed 2016-08-15 |
| 2016-03-31 | $6.82M 10-Q · filed 2016-05-11 |
| 2015-12-31 | $10.84M 10-K · filed 2018-03-16 |
| 2015-09-30 | $4.20M 10-Q · filed 2015-11-12 |
| 2015-06-30 | $4.58M 10-Q · filed 2015-08-13 |
| 2015-03-31 | $12.61M 10-Q · filed 2015-05-15 |
| 2014-12-31 | $23.62M 10-K · filed 2017-03-29 |
| 2014-09-30 | $35.66M 10-Q · filed 2014-11-14 |
| 2014-06-30 | $48.94M 10-Q · filed 2014-08-14 |
| 2014-03-31 | $64.36M 10-Q · filed 2014-05-15 |
| 2013-12-31 | $80.90M 10-K · filed 2016-03-28 |
| 2012-12-31 | -$158.31M 10-K · filed 2015-03-30 |
| 2011-12-31 | -$138.42M 10-K · filed 2015-03-30 |
| 2010-12-31 | -$108.72M 10-K · filed 2014-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |